BRIEF-Aquestive Therapeutics Announces FDA Issuance Of Complete Response Letter For Anaphylm

Reuters

Yesterday

BRIEF-Aquestive <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces FDA Issuance Of Complete Response Letter For Anaphylm

Feb 2 (Reuters) - Aquestive Therapeutics Inc AQST.O:

AQUESTIVE THERAPEUTICS ANNOUNCES FDA ISSUANCE OF COMPLETE RESPONSE LETTER FOR ANAPHYLM™
AQUESTIVE THERAPEUTICS INC - DEFICIENCIES LIMITED TO PACKAGING AND ADMINISTRATION
AQUESTIVE THERAPEUTICS INC - COMPANY EXPECTS TO RESUBMIT AS EARLY AS Q3 2026
AQUESTIVE THERAPEUTICS INC - PLANS TO SUBMIT IN CANADA AND EU BY END OF 2026
AQUESTIVE THERAPEUTICS INC: PLANS TO REQUEST RAPID REVIEW BY FDA
AQUESTIVE THERAPEUTICS INC - COMPANY ANTICIPATES ENDING 2026 WITH SIGNIFICANT CASH

Source text: ID:nGNX1FQjSM

Further company coverage: AQST.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2608086930"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608086930\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608086930?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608086930","market":"nz","top_or_hot":-1,"title":"BRIEF-Aquestive Therapeutics Announces FDA Issuance Of Complete Response Letter For Anaphylm","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces FDA Issuance Of Complete Response Letter For Anaphylm</title></head><body><p><span>Feb 2 (Reuters)</span><span> - </span>Aquestive Therapeutics Inc <span>AQST.O</span>:</p><ul><li><p>AQUESTIVE THERAPEUTICS ANNOUNCES FDA ISSUANCE OF COMPLETE RESPONSE LETTER FOR ANAPHYLM™</p></li><li><p>AQUESTIVE THERAPEUTICS INC - DEFICIENCIES LIMITED TO PACKAGING AND ADMINISTRATION</p></li><li><p>AQUESTIVE THERAPEUTICS INC - COMPANY EXPECTS TO RESUBMIT AS EARLY AS Q3 2026</p></li><li><p>AQUESTIVE THERAPEUTICS INC - PLANS TO SUBMIT IN CANADA AND EU BY END OF 2026</p></li><li><p>AQUESTIVE THERAPEUTICS INC: PLANS TO REQUEST RAPID REVIEW BY FDA</p></li><li><p>AQUESTIVE THERAPEUTICS INC - COMPANY ANTICIPATES ENDING 2026 WITH SIGNIFICANT CASH</p></li></ul><p>Source text: <span>ID:nGNX1FQjSM</span></p><p>Further company coverage: <span>AQST.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Aquestive Therapeutics Announces FDA Issuance Of Complete Response Letter For Anaphylm</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Aquestive Therapeutics Announces FDA Issuance Of Complete Response Letter For Anaphylm\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-02 20:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aquestive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces FDA Issuance Of Complete Response Letter For Anaphylm</title></head><body><p><span>Feb 2 (Reuters)</span><span> - </span>Aquestive Therapeutics Inc <span>AQST.O</span>:</p><ul><li><p>AQUESTIVE THERAPEUTICS ANNOUNCES FDA ISSUANCE OF COMPLETE RESPONSE LETTER FOR ANAPHYLM™</p></li><li><p>AQUESTIVE THERAPEUTICS INC - DEFICIENCIES LIMITED TO PACKAGING AND ADMINISTRATION</p></li><li><p>AQUESTIVE THERAPEUTICS INC - COMPANY EXPECTS TO RESUBMIT AS EARLY AS Q3 2026</p></li><li><p>AQUESTIVE THERAPEUTICS INC - PLANS TO SUBMIT IN CANADA AND EU BY END OF 2026</p></li><li><p>AQUESTIVE THERAPEUTICS INC: PLANS TO REQUEST RAPID REVIEW BY FDA</p></li><li><p>AQUESTIVE THERAPEUTICS INC - COMPANY ANTICIPATES ENDING 2026 WITH SIGNIFICANT CASH</p></li></ul><p>Source text: <span>ID:nGNX1FQjSM</span></p><p>Further company coverage: <span>AQST.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AQST","symbol_name":"Aquestive Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUAB1H1WW:1","article_id":"2608086930","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608086930","pubTimestamp":1770035719,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Aquestive Therapeutics Announces FDA Issuance Of Complete Response Letter For AnaphylmFeb 2 (Reuters) - Aquestive Therapeutics Inc AQST.O:AQUESTIVE THERAPEUTICS ANNOUNCES FDA ISSUANCE OF COMPLET","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AQST":"Aquestive Therapeutics Inc.","BK4007":"制药"},"translate_title":"BRIEF-Aquestive Therapeutics宣布FDA发布过敏反应的完整回复函","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AQST":0.9},"content_text":"BRIEF-Aquestive Therapeutics Announces FDA Issuance Of Complete Response Letter For AnaphylmFeb 2 (Reuters) - Aquestive Therapeutics Inc AQST.O:AQUESTIVE THERAPEUTICS ANNOUNCES FDA ISSUANCE OF COMPLETE RESPONSE LETTER FOR ANAPHYLM™AQUESTIVE THERAPEUTICS INC - DEFICIENCIES LIMITED TO PACKAGING AND ADMINISTRATIONAQUESTIVE THERAPEUTICS INC - COMPANY EXPECTS TO RESUBMIT AS EARLY AS Q3 2026AQUESTIVE THERAPEUTICS INC - PLANS TO SUBMIT IN CANADA AND EU BY END OF 2026AQUESTIVE THERAPEUTICS INC: PLANS TO REQUEST RAPID REVIEW BY FDAAQUESTIVE THERAPEUTICS INC - COMPANY ANTICIPATES ENDING 2026 WITH SIGNIFICANT CASHSource text: ID:nGNX1FQjSMFurther company coverage: AQST.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}